Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model

Microscopy Research and Technique

Volumn 53, Issue 3, 2001, Pages 193-211

  Knyihár Csillik, Elizabeth ^a   Tajti, János ^a   Chadaide, Zoltán ^b   Csillik, Bertalan ^a,c   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c Institute for Biotechnology Szeged   (Hungary)

Author keywords

CGRP; Electrical stimulation; Gasserian ganglion; Headache; Immunocytochemistry

Indexed keywords

BLOOD; BLOOD VESSELS; BRAIN; COLLAGEN; MUSCULOSKELETAL SYSTEM; NITRIC OXIDE; PEPTIDES;

CALCITONIN GENE-RELATED PEPTIDES; DURA MATER; ELECTRICAL STIMULATIONS; GASSERIAN GANGLION; HEADACHE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; NERVE FIBERS; NEUROPEPTIDES; NITRIC OXIDE SYNTHASES;

DISINTEGRATION;

CALCITONIN GENE RELATED PEPTIDE; ELETRIPTAN; GLYCERYL TRINITRATE; NEUROPEPTIDE; NITRIC OXIDE SYNTHASE; SEROTONIN AGONIST; SUMATRIPTAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DURA MATER; FEMALE; HEADACHE; IMMUNOHISTOCHEMISTRY; MALE; MIGRAINE; NERVE STIMULATION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; TRIGEMINUS GANGLION;

EID: 0035340268     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.1084     Document Type: Article

References (58)

1. Andres KH, During M, Muszynski K, Schmidt RF. 1987. Nerve fibers and their terminals of the dura mater encephali of the rat. Anat Embryol 175:289-301.
2. Ashina M, Bendtsen L, Jensen R, Schiffer S, Olesen J. 1999. Increased plasma levels of CGRP in migraine. Cephalalgia 19:346.
3. Beattie DT, Connor HE, Feniuk W, Humphrey PPA. 1994. The pharmacology of sumatriptan. Rev Contemp Pharmacother 5:285-294
4. Bennett V, Gilligan DM. 1993. The spectrin-based membrane skeleton and micron-scale organization of the plasma membrane. Annu Rev Cell Biol 9:27-66
5. Berger RJ, Zuccarello M, Keller JT. 1994. Nitric oxide synthase immunoreactivity in the rat dura mater. NeuroReport 5:519-521
6. Boess FG, Martin IL. 1994. Molecular biology of 5-HT receptors. Neuropharmacology 33:275-317
7. Buzzi G, Moskowitz MA. 1992. The trigemino-vascular system and migraine. Pathol Biol (Paris) 40:313-317.
8. Buzzi G, Carter WB, Shimizu T, Heath H, Moskowitz MA. 1991. Dihydroergotamine and sumatriptane attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 40: 1193-1200.
9. Dechant KL, Clissold SP. 1992. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 43:776-798
10. Durham PL, Russo AF. 1998. Serotonergic repression of mitogen-activated protein kinase control of the calcitonin gene-related peptide enhancer. Mol Endocrine 12:1002-1009.
11. Durham PL, Russo AF. 1999. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci 19:3423-3429.
12. 1 receptor activation. J Neurosci 17:9545-9553.
13. Edvinsson L, Uddman R. 1981. Adrenergic, cholinergic and peptidergic nerve fibres in dura mater: involvement in headache? Cephalalgia 1:175-179
14. Fujimori H, Pan-Hu H. 1991. Effect of nitric oxide on L-[3H] glutamate binding to rat brain synaptic membranes. Brain Res 554:355-357
15. Goadsby PJ, Edvinsson L. 1993. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48-56.
16. Goadsby PJ, Edvinsson L. 1994. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attack therapies. Brain 117:427-434
17. Goadsby PJ, Edvinsson L, Ekman R. 1988. Release of vasoactive peptide in the extracerebral circulation of man and the cat during activation of the trigemino-vascular system. Ann Neurol 23:193-196.
18. Goadsby PJ, Edvinsson L, Ekman R. 1990. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:1873-1878.
19. Henkes H, May A, Kühne D, Berg-Dammer E, Diener HC. 1996. Sumatriptan: vasoactive effect on human durai vessels, demonstrated by subselective angiography. Cephalalgia 16:224-230
20. 1B/1D) agonists in a model of trigeminovascular nociception in cat. Exp Neurol 150:45-51.
21. 1B/1D agonists and endopeptidase 24.11. Br J Pharmacol 108:331-335
22. Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. 1991. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 31:282-290
23. Jansen J, Edvinsson L, Mortensen A, Olesen J. 1992. Sumatriptan is a potent vasoconstrictor of human durai arteries via a 5-HT1-like receptor. Cephalalgia 12: 202-205
24. Keller JT, Marfurt CF. 1991. Peptidergic and serotoninergic innervation of the rat dura mater. J Comp Neurol 309:515-534.
25. Knyihár-Csillik E, Tajti J, Samsam M, Sáry G, Vécsei L. 1995. Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a ossible model of migraine headache. Neurosci Lett 184: 189-192.
26. Knyihár-Csillik E, Vécsei L. 1999. Effect of a nitric oxide donor on nitroxergic nerve fibers in the rat dura mater. Neurosci Lett 260: 97-100
27. Knyihár-Csillik E, Tajti J, Samsam M, Sáry G, Slezák S, Vécsei L. 1997. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J Neurosci Res 48:449-464.
28. Knyihár-Csillik E, Tajti J, Csillik AE, Sáry G, Chadaide Z, Bohata C, Vécsei, L. 1999. Effects of eletriptan (Pfizer) on the immunohistochemical structure of the rat dura mater, caudal trigeminal nucleus and upper cervical spinal cord. Cephalalgia Hungarica 5:42-43.
29. Kovács K, Kapócs G, Widerlow E, Ekman R, Vécsei L, Jelencsik I, Csanda E. 1991. Suboccipital cerebrospinal fluid and plasma concentrations of corticotropin-releasing hormone and calcitonin gene-related peptide in patients with common migraine. Nord Psykiatr Tridsskr 45:11-16.
30. Marchesi VT. 1985. Stabilizing infrastructure of cell membranes. Annu Rev Cell Biol 1:531-561.
31. Montague PR, Gally JA, Edelman GM. 1991. Spatial signaling in development and function of neural connections. Cereb Cortex 1:119-220.
32. Moskowitz MA. 1984. The neurobiology of vascular head pain. Ann Neurol 16:157-168.
33. Moskowitz MA. 1992. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 13:307-311.
34. Nei K, Matsuyama S, Shuntoh H, Tanaka C. 1996. NMDA receptor activation induces glutamate release through nitric oxide synthesis in guinea pig dentate gyrus. Brain Res 728:105-110
35. O'Connor TP, van der Kooy D. 1988. Enrichment of a vasoactive neuropeptide (calcitonin gene-related peptide) in the trigeminal sensory projection to the intracranial arteries. J Neurosci 8:2468-2476
36. Ochs S, Pourmand P, Jersild RA. 1996. Origin of beading constrictions at the axolemma: presence in unmyelinated axons and after β, β′-iminodipropionitrile degradation of the cytoskeleton. Neuroscience 70:1081-1096
37. Ochs S, Pourmand P, Jersild RA, Friedman RN. 1997. The origin and nature of beading: a reversible transformation of the shape of nerve fibers. Prog Neurobiol 52: 391-426
38. Penfield W. 1934. A contribution to the mechanism of intracranial pain. Proc Assoc Res Nerv Ment Dis 15:399-415.
39. Peroutka SJ. 1993. Serotonin (5-Hydroxytryptamine) receptor subtypes: clinical relevance. In: Smith B, Adelman G, editors. Neuroscience year. Suppl 3 to the Encyclopedia of Neuroscience. Boston-Basel-Berlin: Birkhauser. p 145-147.
40. Pitman V. 1999. Headache recurrence following single dosis of oral eletriptan: review of clinical trial experience. Cephalalgia 19:354.
41. Poole PH, Haughie SR. 1999. Treatment of headache with a second dose of oral eletriptan: meta analysis across phase III clinical trials. Cephalalgia 19:354-355
42. Pryse-Phillips W. 1999.Comparison of oral eletriptan (40-80 mg) and oral sumatriptan (50-100 mg) for the treatment of acute migraine: a randomised, placebo-controlled trial in sumatriptan-naive patients. Cephalalgia 19:355
43. Pumplin DW, Bloch RJ. 1993. The membrane skeleton. Trends Cell Biol 3:113-117
44. Russell MB, Holm-Thomson OE, Nielsen MR, Cleal A, Pilgrim AJ, Olesen J. 1994. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia 14:291-296
45. Saxena PR. 1994. The pathogenesis and pharmacology of migraine. Rev Contemp Pharmacother 5:259-269
46. Saxena PR. 1999. Pharmacology of triptans: are they different? Cephalalgia 19:296.
47. Schneider JS, Denaro JJ, Olezabal VE, Leard HO. 1981. Stereotactic atlas of the trigeminal ganglion in rat, cat and monkey. Brain Res Bull 7:93-95.
48. Schoenen J. 1997. Acute migraine therapy: the newer drugs. Curr Opin Neurol 10:237-243.
49. Shepheard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ. 1995. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 34:255-262.
50. Sternberger LA, Hardy PH, Cusulis JJ. 1970. The unlabeled antibody enzyme method of immunocytochemistry. J Histochem Cytochem 18:315-335
51. Tajti J, Uddman R, Möller S, Sundler F, Edvinsson L. 1999. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Autonom Nerv Syst 76:176-183.
52. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. 1985. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide, trigeminal origin and coexistence with substance P. Neurosci Lett 62:131-136.
53. Wang N, Butler JP, Ingber DE. 1993. Mechanotransduction across the cell surface and through the cytoskeleton. Science 260:1124-1127.
54. Welch KMA. 1993. Drug therapy of migraine. New Engl J Med 329: 1476-1483
55. Wells N. 1999. Comparison of the effectiveness of oral eletriptan (40-80 mg) and oral sumatriptan (50-100 mg) in reducing the time loss and overall impact of migraine attacks. Cephalalgia 19:354.
56. Wilkinson M, Pfaffenrath V, Schoenen J, Diener HC, Steiner TJ. 1995. Migraine and cluster headache: their management with sumatriptan: a critical review of current clinical experience. Cephalalgia 15:337-357
57. Zagami AS, Goadsby PJ, Edvinsson L. 1990. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 16:69-75
58. Zamboni L, DeMartino C. 1967. Buffered picric acid-formaldehyde: a new rapid fixation for electron microscopy. J. Cell Biol. 35:18A.